

Colorectal Disease

The official journal of the:
Association of Coloproctology of Great Britain and Ireland
European Society of Coloproctology
Asociación Española de Coloproctología
Malaysian Society of Colorectal Surgeons

ISSN 1462-8910 (Print)
ISSN 1463-1318 (Online)

VOLUME 26
SUPPLEMENT 2
SEPTEMBER 2024



ESCP's 19th Scientific and Annual Conference

25–27 September 2024
Thessaloniki, Greece

WILEY

View this journal online at wileyonlinelibrary.com/journal/codi

Colorectal Disease

Volume 26 Supplement 2 September 2024

ESCP's 19th Scientific and Annual Conference
25–27 September 2024
Thessaloniki, Greece

This abstract book has been produced using author-supplied copy. Editing has been restricted to some corrections of spelling and style where appropriate. No responsibility is assumed for any claims, instructions, methods or drug dosages contained in the abstracts: it is recommended that these are verified independently.

WILEY

Contents

ESCP's 19th Scientific and Annual Conference, 25–27 September 2024,
Thessaloniki, Greece

	Pages
Orals	4–19
Oral Visual Poster	20–30
ePosters	31–388
New Trial	389–392
Author Index	393–416

Results: A total of eighty-three elements were defined. Thirty proteins among them were differentially expressed proteins (DEPs), including eighteen up-regulated proteins, and twelve down regulated proteins found in regional lymph node metastasis rather than primary colon cancer. MS analysis was validated by the level of Fibrinogen- β and Serpin B5 using western blotting assay. The metastatic role in Serpin B5 expression was verified that loss of Serpin B5 expression was related to an increased level of snail and induced cellular migration and proliferation in colon cancer cell lines.

Conclusion: In conclusion, we identified thirty DEPs between regional lymph node metastasis and primary colon cancer by proteomics analysis from five patient samples. Among them, alternative levels of Serpin B5 induced metastasis and cellular proliferation in cancer cell lines. Further studies are needed to demonstrate the mechanism of colon cancer progression and survival rate with changes in Serpin B5 expression depending on the metastatic regions.

Disclosure of Interest: None declared.

PO045 | Microsatellite instability-high in stage IV colorectal cancer: Prevalence, and clinicopathological characteristics in Malaysia

N. A. Izhar^{1,1}; M. Y. Sainal^{1,2}; M. I. Mohd Salmi^{1,2}; F. Elagili^{1,2}, A. Md Nor^{1,2}

¹Department of Surgery, Sultan Ahmad Shah Medical Centre;

²Department of Surgery, International Islamic University Malaysia, Kuantan, Malaysia

Aim: The purpose of this study was to estimate the prevalence of Microsatellite Instability High (MSI-H) in stage IV colorectal cancer in Malaysians and to describe MSI-H clinicopathological characteristics.

Method: All patients with stage IV colorectal cancer who underwent surgical resection of the primary tumor between January 2017 and December 2020 were included in the single-center retrospective study. MSI status was determined. Clinicopathological features were evaluated.

Results: Among 42 patients with stage IV colorectal cancer, 4 patients (10%) had MSI-H (57% were men) with an average age of 58 ± 21 years and were related to left-sided colonic origin, adenocarcinoma, moderately differentiated, lymphovascular invasion, single-organ metastasis, peritoneal metastasis, and Malay race. The average survival durations for MSI-H and Microsatellite Stable (MSS) were 15 ± 14 and 18 ± 16 months, respectively ($p=0.77$).

Conclusion: In this study, MSI-H was detected in 10% of individuals with stage IV colorectal cancer. However, our data highlight the features and prognostic relevance of MSI-H in Malaysian stage IV colorectal cancer patients.

Reference:

1. Wang, B., Li, F., Zhou, X., Ma, Y., & Fu, W. (2019). Is microsatellite instability-high really a favorable prognostic factor for advanced

colorectal cancer? A meta-analysis. *World Journal of Surgical Oncology*, 17(1). <https://doi.org/10.1186/s12957-019-1706-5>

2. Simanjuntak, Berlian & Jeo, Wifanto & Krisnuhoni, E. (2018). Correlation between microsatellite instability (MSI) and 5-year survival in patients with colorectal cancer. *Journal of Physics: Conference Series*. 1073. 042021. <https://doi.org/10.1088/1742-6596/1073/4/042021>

3. Fujiyoshi, K., Yamamoto, G., Takenoya, T., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., & Akagi, K. (2017). Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. *Anticancer Research (Print)*, 37(1), 239–248. <https://doi.org/10.21873/anticancer.11313>

4. Tan, W. J., Hamzah, J. L. B., Acharyya, S., Foo, F. J., Lim, K. H., Tan, I. B. H., Tang, C. L., & Chew, M. H. (2017). Evaluation of Long-Term outcomes of microsatellite instability status in an Asian cohort of sporadic colorectal cancers. *Journal of Gastrointestinal Cancer*, 49(3), 311–318. <https://doi.org/10.1007/s12029-017-9953-6>

Disclosure of Interest: None declared.

PO046 | Rectal cancer dMMR: A new scenario

A. Manuel¹; S. Gortazar^{1,1}; M. Soria²; J. M. Martín²; E. Sánchez¹; A. Valle¹; M. González Bocanegra¹; V. Jiménez¹; J. L. Ramos¹

¹General and Digestive Surgery; ²Oncology, Hospital Universitario Getafe, Madrid, Spain

Aim: Multimodality treatment with chemo-/radiotherapy (QT, RT) and surgery is the standard in the management of locally advanced rectal cancer (RC), achieving approximately 25% complete response rate, but with marked morbidity and toxic effects.

About 5–10% of CRs have altered repair proteins (dMMR), detectable by immunohistochemistry (IHC). Immunotherapy alone or after neoadjuvant therapy has shown high efficacy as a first line of treatment in these patients.

Method: We present two cases of advanced RC and dMMR with clinical complete response after immunotherapy.

Results: *Case report 1:* 36-year-old woman, recently diagnosed with Lynch syndrome (pathogenic mutation in the MSH6 gene), was referred with a rectal adenocarcinoma at 9 cm from the anal margin T3bN1b. Given the diagnosis of rectal cancer in a patient with dMMR, treatment with dostarlimab was decided. After 3 and 6 months reevaluation with rectoscopy, MRI and PET/CT a complete clinical response was achieved. The patient continues to be monitored by Oncology.

Case report 2: 46-year-old woman diagnosed with a rectal adenocarcinoma 6 cm from de anal margin, T3cN2b.

With the diagnosis of locally advanced neoplasia, a multidisciplinary session decided on neoadjuvant treatment with a long course of RT and QT (TNT).